Turkey’s Biofarma Signs Strategic License Agreement With Korean Pharmaceutical Firm Dong-A
This article was originally published in PharmAsia News
Executive Summary
Biofarma signed a strategic license agreement with South Korean pharma giant Dong A. The deal includes technology transfer by Dong-A to allow Biofarma to produce and sell some of its products in Turkey with the first offering in 2016 slated as a medicine for prostate growth.